Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
DaVitaDVA +1.19%88 ROC (Joel Greenblatt) % is 35.09% as of Mar. 2026, which is 32% above its 10-year median of 26.53. GuruFocus rates DVA with a GF Score™ of 88/100 and a GF Value™ of $174.71 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 668 Healthcare Providers & Services companies, DaVita ranks better than 76.65% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. DaVita's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 35.09%.
The historical rank and industry rank for DaVita's ROC (Joel Greenblatt) % or its related term are showing as below:
DVA'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 19.16 Med: 26.53 Max: 69.92
Current: 35.87
During the past 13 years, DaVita's highest ROC (Joel Greenblatt) % was 69.92%. The lowest was 19.16%. And the median was 26.53%.
DVA's ROC (Joel Greenblatt) % is ranked better than 76.65% of 668
companies
in the Healthcare Providers & Services industry
Industry Median: 12.47
vs DVA: 35.87
DaVita's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 8.40% per year.
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
The historical data trend for DaVita's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DVA vs THC, EHC, ENSG: ROC (Joel Greenblatt) % Comparison
For the Medical Care Facilities subindustry, DaVita's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaVita ROC (Joel Greenblatt) % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaVita's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where DaVita's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 35.09% mean?
DaVita (DVA) has a ROC (Joel Greenblatt) % of 35.09% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on DaVita and its competitors. This is 32% above median its historical median of 26.53. Over the past decade, DaVita's ROC (Joel Greenblatt) % has ranged from 19.16 to 69.92. According to the industry distribution chart, DaVita ranks #156 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 23.4%.
Is DaVita's ROC (Joel Greenblatt) % too high?
DaVita's current ROC (Joel Greenblatt) % of 35.09% is 32% above median its 10-year median of 26.53. Over the past 10 years, this metric has ranged from a low of 19.16 to a high of 69.92. The Healthcare Providers & Services industry median ROC (Joel Greenblatt) % is 12.47. DaVita's value of 35.09% is 181.4% above this industry median. Based on the distribution chart, DaVita ranks #156 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaVita has a GF Score™ of 88/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does DaVita's ROC (Joel Greenblatt) % compare to THC and EHC?
According to the Healthcare Providers & Services industry distribution chart, DaVita ranks #156 out of 668 companies for ROC (Joel Greenblatt) %. This places DaVita in the top 23% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 12.47. DaVita's value of 35.09% is 181.4% above this benchmark. Historically, DaVita's own ROC (Joel Greenblatt) % has ranged from 19.16 to 69.92 over the past decade. While the company's 10-year median is 26.53 vs. the industry median of 12.47, DaVita has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Healthcare Providers & Services company?
The median ROC (Joel Greenblatt) % among Healthcare Providers & Services companies is 12.47, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. DaVita's current ROC (Joel Greenblatt) % of 35.09% is 181.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on DaVita and its competitors. For the Healthcare Providers & Services industry, the median ROC (Joel Greenblatt) % is 12.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. DaVita's current ROC (Joel Greenblatt) % is 35.09%, which is 32% above median its own 10-year median of 26.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaVita stock overvalued right now?
Based on GuruFocus' analysis, DaVita (DVA) is currently considered Significantly Overvalued. The stock's GF Value™ is $174.71, compared to a current price of $235.58 — trading 34.8% above its estimated fair value. The current ROC (Joel Greenblatt) % is 35.09%, which is 32% above median its 10-year median of 26.53 and 181.4% above the Healthcare Providers & Services industry median of 12.47. DaVita's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For DaVita (DVA), the current ROC (Joel Greenblatt) % is 35.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaVita (DVA) Overvalued in 2026?
Based on GuruFocus' analysis, DaVita stock appears to be overvalued.
The current stock price of $235.58 is trading 34.8% above its estimated GF Value™ of $174.71.
GuruFocus considers DaVita to be Significantly Overvalued.
Key valuation signals for DVA:
ROC (Joel Greenblatt) %: 35.09% (32% above median its 10-year median of 26.53)
GF Value™: $174.71 vs. price of $235.58 (34.8% above fair value)
Industry Position: 181.4% above the Healthcare Providers & Services median (#156 of 668)
No single metric tells the full story. See the DVA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
88GF Score
Get the complete analysis for DVA
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DVA has been successfully added to your 
